Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

196 questions in 33 reviews · Urology

current versions

No studies 196 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Potassium paraaminobenzoate vs placebo Outcomes ( · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Outcomes ( · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Patient‐reported ability to have intercourse · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Quality of life · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional betamethasone vs saline Outcomes ( · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional betamethasone vs saline Patient‐reported ability to have intercourse · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional betamethasone vs saline Quality of life · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional betamethasone vs saline Degree of penile curvature · men with Peyronie's disease (not defined) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional collagenase vs placebo Outcomes ( · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional collagenase vs placebo Patient‐reported ability to have intercourse · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional collagenase vs placebo Treatment‐related adverse effects · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Potassium paraaminobenzoate vs placebo Quality of life · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional collagenase vs placebo Discontinuation from treatment · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional collagenase vs placebo Outcomes ( · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional collagenase vs placebo Patient‐reported ability to have intercourse · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional verapamil vs saline (short‐term) Outcomes ( · men with Peyronie's disease (palpable plaque or pain) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional verapamil vs saline (short‐term) Quality of life · men with Peyronie's disease (palpable plaque or pain) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional verapamil vs saline (short‐term) Discontinuation from treatment · men with Peyronie's disease (palpable plaque or pain) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional Botox vs placebo Outcomes ( · men with Peyronie's disease (stable phase) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional Botox vs placebo Patient‐reported ability to have intercourse · men with Peyronie's disease (stable phase) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional Botox vs placebo Treatment‐related adverse effects · men with Peyronie's disease (stable phase) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional Botox vs placebo Degree of penile curvature · men with Peyronie's disease (stable phase) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional Botox vs placebo Discontinuation from treatment · men with Peyronie's disease (stable phase) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Extracorporeal shock wave treatment (ESWT) vs sham Outcomes ( · men with Peyronie's disease (penile plaque with pain and/or curvature, diagnosis of disease: from acute (< 12 months)… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Potassium paraaminobenzoate vs placebo Degree of penile curvature · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Penile traction therapy vs no treatment (short‐term) Outcomes ( · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Penile traction therapy vs no treatment (short‐term) Patient‐reported ability to have intercourse · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Outcomes ( · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Patient‐reported ability to have intercourse · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Quality of life · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Percutaneous nephrolithotomy vs retrograde intrarenal surgery Unplanned medical visits Assumed MCID: 5% · adults with renal stones Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults (2023) · Cochrane	no estimate extracted	NR	No studies
Percutaneous nephrolithotomy vs retrograde intrarenal surgery Quality of life Assumed MCID: NA · adults with renal stones Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Adverse events (grade 3 to 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Time to initiation of first subsequent therapy · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR MSKCC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Serious adverse events (SAEs) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR IMDC risk groups · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life (QoL) We reported this outcome narratively in this review. Here, long‐term results (i.e., at the end of treatment) are presented. In the comparison PAZ versus SUN, QoL was measured using FACIT‐F (score range 0‐52; higher scores rep... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Adverse events (grade 3 or 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Time to initiation of first subsequent therapy · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR MSKCC risk groups · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR IMDC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the… First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network… (2023) · Cochrane	no estimate extracted	NR	No studies
PAE vs sham Erectile function · men with lower urinary tract symptoms suggesting benign prostatic hyperplasia Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign… (2022) · Cochrane	no estimate extracted	NR	No studies